Evidence map›Paper›PMID 31709774›Full record

ArticleEMBO molecular medicine2019

Immune-mediated ECM depletion improves tumour perfusion and payload delivery.

Yen Ling Yeow, Venkata Ramana Kotamraju, Xiao Wang, Meenu Chopra, Nasibah Azme, Jiansha Wu, Tobias D Schoep, Derek S Delaney, Kirk Feindel, Ji Li and 21 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Molecular ZIP codes in targeted drug delivery.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. The matrix in cancer.Nature reviews. Cancer · 2021
    Review
  17. Targeting Tumors Using Peptides.Molecules (Basel, Switzerland) · 2020
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 6 institutions in 2 countries.

Yen Ling YeowHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.
Venkata Ramana KotamrajuCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Xiao WangHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.
Meenu ChopraHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.
Nasibah AzmeHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.
Jiansha WuHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.
Tobias D SchoepTelethon Kids Institute, Subiaco, WA, Australia.
Derek S DelaneyHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.ORCID 0000-0002-1185-121X
Kirk FeindelCentre for Microscopy, Characterisation & Analysis, The University of Western Australia, Perth, WA, Australia.
Ji LiHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.
Kelsey M KennedyDepartment of Electrical, Electronic & Computer Engineering, School of Engineering, The University of Western Australia, Perth, WA, Australia.
Wes M AllenHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.
Brendan F KennedyHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.
Irma LarmaCentre for Microscopy, Characterisation & Analysis, The University of Western Australia, Perth, WA, Australia.
David D SampsonCentre for Microscopy, Characterisation & Analysis, The University of Western Australia, Perth, WA, Australia.
Lisa M MahakianDepartment of Biomedical Engineering, University of California Davis, Davis, CA, USA.
Brett Z FiteDepartment of Biomedical Engineering, University of California Davis, Davis, CA, USA.
Hua ZhangDepartment of Biomedical Engineering, University of California Davis, Davis, CA, USA.
Tomas FrimanCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Aman P MannCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Farah A AzizSir Charles Gairdner Hospital, Perth, WA, Australia.
M Priyanthi KumarasinghePathWest Laboratory Medicine, QE2 Medical Centre, Perth, WA, Australia.
Mikael JohanssonSir Charles Gairdner Hospital, Perth, WA, Australia.
Hooi C EeSir Charles Gairdner Hospital, Perth, WA, Australia.
George YeohHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.
Lingjun MouSir Charles Gairdner Hospital, Perth, WA, Australia.
Katherine W FerraraDepartment of Biomedical Engineering, University of California Davis, Davis, CA, USA.
Hector BilliranCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Ruth GanssHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.
Erkki RuoslahtiCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Juliana HamzahHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Perth, WA, Australia.ORCID 0000-0002-3802-5073
The University of Western Australia · AUSanford Burnham Prebys Medical Discovery Institute · USSir Charles Gairdner Hospital · AUUniversity of California, Davis · USPathwest Laboratory Medicine · AUThe Kids Research Institute Australia · AU

Funding

Image-guided ultrasound therapy and drug delivery in pancreatic cancerR01CA210553 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FERRARA, KATHERINE W · 2016 to 2020
$3.2M
A nanosystem for tumor treatment and imagingR01CA188883 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI RUOSLAHTI, ERKKI · 2014 to 2018
$2.0M
Cancer Council Western AustraliaCenter for Strategic Scientific Initiatives, National Cancer Institute (CSSI, NCI) CA188883Department of Health|National Health and Medical Research Council (NHMRC) APP1046507Department of Health|National Health and Medical Research Council (NHMRC) APP1058073Department of Health|National Health and Medical Research Council (NHMRC) APP1121131HHS|NIH|National Cancer Institute (NCI) NIHCA210553NCI NIH HHS R01 CA188883University, State and Commonwealth Governments
6 · The paper itself

Abstract

High extracellular matrix (ECM) content in solid cancers impairs tumour perfusion and thus access of imaging and therapeutic agents. We have devised a new approach to degrade tumour ECM, which improves uptake of circulating compounds. We target the immune-modulating cytokine, tumour necrosis factor alpha (TNFα), to tumours using a newly discovered peptide ligand referred to as CSG. This peptide binds to laminin-nidogen complexes in the ECM of mouse and human carcinomas with little or no peptide detected in normal tissues, and it selectively delivers a recombinant TNFα-CSG fusion protein to tumour ECM in tumour-bearing mice. Intravenously injected TNFα-CSG triggered robust immune cell infiltration in mouse tumours, particularly in the ECM-rich zones. The immune cell influx was accompanied by extensive ECM degradation, reduction in tumour stiffness, dilation of tumour blood vessels, improved perfusion and greater intratumoral uptake of the contrast agents gadoteridol and iron oxide nanoparticles. Suppressed tumour growth and prolonged survival of tumour-bearing mice were observed. These effects were attainable without the usually severe toxic side effects of TNFα.

Indexed as

AnimalsCell LineCell Surface Display TechniquesContrast MediaExtracellular MatrixFemaleFerric CompoundsGadoliniumHeterocyclic CompoundsHumansMaleMiceNanoparticlesOrganometallic CompoundsTumor Necrosis Factor-alphaContrast MediaFerric Compoundsferric oxideGadoliniumgadoteridolHeterocyclic CompoundsOrganometallic CompoundsTumor Necrosis Factor-alphaextracellular matriximmune cellspeptidesolid tumourtumour necrosis factor alpha

Identifiers

PMID31709774
PMCPMC6895610
OpenAlexW2983597330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.